Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MaxCyte, Inc. - Common Stock
(NQ:
MXCT
)
0.6896
-0.0504 (-6.81%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MaxCyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
A Look at MaxCyte's Upcoming Earnings Report
↗
May 06, 2025
Via
Benzinga
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
April 10, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
March 12, 2025
Via
Benzinga
These stocks are moving in today's after hours session
↗
March 11, 2025
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
March 11, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For March 11, 2025
↗
March 11, 2025
Via
Benzinga
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 12, 2025
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for...
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
February 07, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
January 30, 2025
From
Glancy Prongay & Murray LLP
Via
Business Wire
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
January 30, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MarketBeat Week in Review – 01/20 - 01/24
January 25, 2025
Stocks surged higher as investors reacted positively to dovish tariff news; next week will be highlighted by the Federal Reserve meeting and some tech earnings
Via
MarketBeat
Topics
Economy
Government
World Trade
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
January 23, 2025
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
Via
MarketBeat
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
January 13, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Retirement of Board Member Art Mandell
December 23, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
December 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
November 13, 2024
Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
November 06, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in Two Upcoming Investor Conferences
October 31, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Appoints Cynthia Collins to its Board of Directors
October 15, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
October 11, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
October 10, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
September 16, 2024
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
September 05, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q2 2024
↗
August 06, 2024
MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
August 06, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
July 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
May 29, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
May 22, 2024
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T...
From
MaxCyte, Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
May 08, 2024
Via
Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
May 08, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
